NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma
Gliomas account for 75% of all primary malignant brain tumors in adults and are associated with high mortality. Mounting evidence has shown that NCAPG2 is differentially expressed in various cancers. However, the prognostic value and immune functions of NCAPG2 in low-grade glioma (LGG) remain unreso...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.918606/full |
| _version_ | 1828337730301460480 |
|---|---|
| author | Wenjun Ren Shu Yang Xi Chen Jishu Guo Heng Zhao Ruihan Yang Zhi Nie Li Ding Lei Zhang |
| author_facet | Wenjun Ren Shu Yang Xi Chen Jishu Guo Heng Zhao Ruihan Yang Zhi Nie Li Ding Lei Zhang |
| author_sort | Wenjun Ren |
| collection | DOAJ |
| description | Gliomas account for 75% of all primary malignant brain tumors in adults and are associated with high mortality. Mounting evidence has shown that NCAPG2 is differentially expressed in various cancers. However, the prognostic value and immune functions of NCAPG2 in low-grade glioma (LGG) remain unresolved. In the present study, we revealed that NCAPG2 was up-regulated in LGG, and its higher expression was associated with adverse clinical outcomes and poor clinical characteristics, including WHO grade, IDH mutation, 1p/19q codeletion, and primary therapy outcome. The results of the Cox regression analysis revealed that NCAPG2 was an independent factor for the prognosis of low-grade glioma. Meanwhile, we also established a nomogram based on NCAPG2 to predict the 1-, 3-, or 5-year survival in LGG patients. Furthermore, we found that Copy number variation (CNV) and DNA hypomethylation results in its overexpression in LGG. In addition, functional annotation confirmed that NCAPG2 was mainly involved in the immune regulation and WNT signaling pathways. Finally, we determined that increased expression of NCAPG2 was correlated with infiltration levels of various immune cells and immune checkpoint in LGG. Importantly, we found that NCAPG2 was highly expressed in glioma stem cells lines and knockdown of NCAPG2 significantly inhibited the self-renewal ability of GSC. This is the first study to identify NCAPG2 as a new potential prognostic biomarker and characterize the functional roles of NCAPG2 in the progression of LGG, and provides a novel potential diagnostic and therapeutic biomarker for LGG in the future. |
| first_indexed | 2024-04-13T22:19:00Z |
| format | Article |
| id | doaj.art-2868d12c3c7c4acbb2326b987e6a2df8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T22:19:00Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-2868d12c3c7c4acbb2326b987e6a2df82022-12-22T02:27:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.918606918606NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade GliomaWenjun Ren0Shu Yang1Xi Chen2Jishu Guo3Heng Zhao4Ruihan Yang5Zhi Nie6Li Ding7Lei Zhang8Department of Cardiovascular Surgery, The First People’s Hospital of Yunnan Province, Kunming, ChinaDepartment of Neurology, The First People’s Hospital of Yunnan Province, Kunming, ChinaDepartment of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, ChinaInstitute for Ecological Research and Pollution Control of Plateau Lakes, School of Ecology and Environmental Science, Yunnan University, Kunming, ChinaDepartment of Neurology, The First People’s Hospital of Yunnan Province, Kunming, ChinaDepartment of Neurology, The First People’s Hospital of Yunnan Province, Kunming, ChinaDepartment of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Neurology, The First People’s Hospital of Yunnan Province, Kunming, ChinaDepartment of Neurology, The First People’s Hospital of Yunnan Province, Kunming, ChinaGliomas account for 75% of all primary malignant brain tumors in adults and are associated with high mortality. Mounting evidence has shown that NCAPG2 is differentially expressed in various cancers. However, the prognostic value and immune functions of NCAPG2 in low-grade glioma (LGG) remain unresolved. In the present study, we revealed that NCAPG2 was up-regulated in LGG, and its higher expression was associated with adverse clinical outcomes and poor clinical characteristics, including WHO grade, IDH mutation, 1p/19q codeletion, and primary therapy outcome. The results of the Cox regression analysis revealed that NCAPG2 was an independent factor for the prognosis of low-grade glioma. Meanwhile, we also established a nomogram based on NCAPG2 to predict the 1-, 3-, or 5-year survival in LGG patients. Furthermore, we found that Copy number variation (CNV) and DNA hypomethylation results in its overexpression in LGG. In addition, functional annotation confirmed that NCAPG2 was mainly involved in the immune regulation and WNT signaling pathways. Finally, we determined that increased expression of NCAPG2 was correlated with infiltration levels of various immune cells and immune checkpoint in LGG. Importantly, we found that NCAPG2 was highly expressed in glioma stem cells lines and knockdown of NCAPG2 significantly inhibited the self-renewal ability of GSC. This is the first study to identify NCAPG2 as a new potential prognostic biomarker and characterize the functional roles of NCAPG2 in the progression of LGG, and provides a novel potential diagnostic and therapeutic biomarker for LGG in the future.https://www.frontiersin.org/articles/10.3389/fonc.2022.918606/fulllow-grade gliomaNCAPG2prognostic biomarkerimmune infiltrationglioma stem cell |
| spellingShingle | Wenjun Ren Shu Yang Xi Chen Jishu Guo Heng Zhao Ruihan Yang Zhi Nie Li Ding Lei Zhang NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma Frontiers in Oncology low-grade glioma NCAPG2 prognostic biomarker immune infiltration glioma stem cell |
| title | NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma |
| title_full | NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma |
| title_fullStr | NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma |
| title_full_unstemmed | NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma |
| title_short | NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma |
| title_sort | ncapg2 is a novel prognostic biomarker and promotes cancer stem cell maintenance in low grade glioma |
| topic | low-grade glioma NCAPG2 prognostic biomarker immune infiltration glioma stem cell |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.918606/full |
| work_keys_str_mv | AT wenjunren ncapg2isanovelprognosticbiomarkerandpromotescancerstemcellmaintenanceinlowgradeglioma AT shuyang ncapg2isanovelprognosticbiomarkerandpromotescancerstemcellmaintenanceinlowgradeglioma AT xichen ncapg2isanovelprognosticbiomarkerandpromotescancerstemcellmaintenanceinlowgradeglioma AT jishuguo ncapg2isanovelprognosticbiomarkerandpromotescancerstemcellmaintenanceinlowgradeglioma AT hengzhao ncapg2isanovelprognosticbiomarkerandpromotescancerstemcellmaintenanceinlowgradeglioma AT ruihanyang ncapg2isanovelprognosticbiomarkerandpromotescancerstemcellmaintenanceinlowgradeglioma AT zhinie ncapg2isanovelprognosticbiomarkerandpromotescancerstemcellmaintenanceinlowgradeglioma AT liding ncapg2isanovelprognosticbiomarkerandpromotescancerstemcellmaintenanceinlowgradeglioma AT leizhang ncapg2isanovelprognosticbiomarkerandpromotescancerstemcellmaintenanceinlowgradeglioma |